Summary of Proposed Investment
Project Number
10215
Company Name
Bosnalijek d.d.
Date SPI Disclosed
Jul 20, 2000
Country
Bosnia and Herzegovina
Industry
Health, Education and Life Sciences
Projected Board Date
Aug 21, 2000
Status
Completed
Sector
Pharmaceuticals and Medicine
Department
Gbl Ind, Manufact, Agribus & Services
Environmental Category
B - Limited
Previous Events
Approved : Aug 21, 2000
Signed : Oct 18, 2000
Invested : Dec 27, 2000
Project Description
The company is the only manufacturer of over-the-counter, prescription and hospital pharmaceuticals in BiH. Bosnalijek is a generic drug manufacturer. Presently it produces a range of 138 drugs in solid oral forms, ampoules, syrups, solutions, ointments and creams, of which 90% are produced according to its own proprietary technology.
The purpose of the project is to complete the reconstruction and modernization of the solid oral drug plant with the addition of tablet coating and packaging equipment.
This project is Phase II of the company''s investment program, which aims to complete the reconstruction of the solid oral drug plant and modernize it with the addition of tablet coating and packing equipment. Phase I of the project consisted of re-building and modernising the tablet and capsules manufacturing operation; this was completed within budget in September 1998. The whole investment is essential to correct manufacturing process defects and to ensure that production will be in compliance with good manufacturing practices (GMP). Hence, the project should secure international GMP certification from the EU and elsewhere which is needed to access export markets. This will further consolidate the company''s market position as a regional player in the production of solid oral drugs.
IFC''s involvement will provide the company and Bosnia''s health sector with long term funding needed to complete a modern drug manufacturing plant and achieve international quality standards and certification and increased exports. The company will also increase its ability to supply the domestic market with drugs that are currently imported. Both will contribute positively to Bosnia''s balance of payments.
The purpose of the project is to complete the reconstruction and modernization of the solid oral drug plant with the addition of tablet coating and packaging equipment.
This project is Phase II of the company''s investment program, which aims to complete the reconstruction of the solid oral drug plant and modernize it with the addition of tablet coating and packing equipment. Phase I of the project consisted of re-building and modernising the tablet and capsules manufacturing operation; this was completed within budget in September 1998. The whole investment is essential to correct manufacturing process defects and to ensure that production will be in compliance with good manufacturing practices (GMP). Hence, the project should secure international GMP certification from the EU and elsewhere which is needed to access export markets. This will further consolidate the company''s market position as a regional player in the production of solid oral drugs.
IFC''s involvement will provide the company and Bosnia''s health sector with long term funding needed to complete a modern drug manufacturing plant and achieve international quality standards and certification and increased exports. The company will also increase its ability to supply the domestic market with drugs that are currently imported. Both will contribute positively to Bosnia''s balance of payments.
Sponsor / Cost / Location
Development Impact
Related ESRS/ERS
Contacts
For Inquiries About the Project, Contact
Mr. Edin Arslanagic
General Manager
Bosnalijek, d.d.
Jukiceva, 55
Sarajevo
Bosnia and Herzegovina
+387 71 665 970
e-mail: blijek@bih.net.ba
General Manager
Bosnalijek, d.d.
Jukiceva, 55
Sarajevo
Bosnia and Herzegovina
+387 71 665 970
e-mail: blijek@bih.net.ba